Atai Beckley Stock Soars on Report of Eli Lilly Takeover Talks

Shares of Atai Beckley Inc. (ATAI) surged more than 52% in pre-market trading after a report from Bloomberg News stated that pharmaceutical giant Eli Lilly (LLY) is in advanced talks to acquire the company. The report, published Wednesday evening, suggested a deal could be announced as soon as this week.

The Potential Acquisition

According to the report, which was also cited by Reuters, Eli Lilly is negotiating to buy the psychedelic drug developer at a premium. Atai Beckley's market capitalization had climbed to approximately $2 billion following a more than twofold increase in its share price over the past year.

Commenting on the news, venture capitalist Magnus Sigurdsson of Systematic Ventures and Iron Pine Ventures suggested the talks may be the result of a structured process Atai began in March for its lead drug, BPL-003. He estimated a potential takeover price in the range of $9 to $11 per share.

Strategic Rationale and Market Impact

Analysts noted the strong strategic fit for Eli Lilly. An acquisition would "add a platform of rapid-acting psychedelic-based therapies and broaden Lilly’s neuroscience portfolio into treatment-resistant depression and other difficult-to-treat psychiatric disorders," BMO Capital Markets analysts wrote in a client note.

Ad

The news triggered a significant, company-specific rally, with the broader S&P 500, Dow Jones, and NASDAQ indices remaining largely flat. The potential deal also lifted shares of sector peers, with RBC Capital Markets analyst Brian Abrahams identifying GH Research as having the "most direct read-across."

Industry Tailwinds

The reported acquisition talks underscore growing interest from major pharmaceutical firms in the once-fringe field of psychedelic medicine. This trend has been bolstered by the commercial success of treatments like Johnson & Johnson’s Spravato and a series of promising clinical trial results across the industry.

A supportive regulatory environment has also provided a tailwind. Atai's stock had already risen in Tuesday's session as investors reacted to final FDA guidance for psychedelic-drug trials. The guidance, which calls for two monitors to be present with a patient during treatment, is seen as beneficial to Atai Beckley’s roughly two-hour clinical model.